Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript
诺和诺德诺和诺德(US:NVO) Seeking Alpha·2026-02-23 20:14

会议信息 - 本次为诺和诺德公司投资者关系会议电话 [1] - 会议由投资者关系主管Michael Novod主持 [1] - 会议内容被录音 [1]

Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript - Reportify